The global newborn screening market size is calculated at USD 3.44 billion in 2024 and is expected to be worth USD 6.46 billion by 2034, expanding at a CAGR of 6.5% from 2024 to 2034.
The newborn screening companies are:
Various factors, such as technological advancements and regulatory frameworks shape the competitive landscape for the newborn screening market. Technological advancements drive competition as companies strive to develop innovative screening technologies with improved accuracy, sensitivity, and speed. Companies may also differentiate themselves by offering comprehensive screening panels covering a wide range of disorders and specialized tests for specific conditions. Regulatory requirements and compliance also influence competition in the newborn screening market. Companies must adhere to regulatory standards and obtain necessary product approvals, which can impact their ability to enter new markets and compete effectively.
Dr. Rich Scott, CEO at Genomics England, commented that the launch of Generation Study for whole genome sequencing for more than 200 genetic conditions in newborn screening is a pivotal moment and emphasized the screening for thousands of children born every year in the UK with a treatable genetic condition. He also added that their collaboration with NHS means that the UK is uniquely placed to test and roll out genomic innovations to improve health and prevent illness.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
